Analysis of the Structural Basis of Specificity of Inhibition of the Abl Kinase by STI571

STI571, a selective inhibitor of Bcr-Abl, has been a successful therapeutic agent in clinical trials for chronic myelogenous leukemia. Chronic phase chronic myelogenous leukemia patients treated with STI571 have durable responses; however, most responding blast phase patients relapse despite continu...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The Journal of biological chemistry 2002-08, Vol.277 (35), p.32214-32219
Hauptverfasser:	Corbin, Amie S, Buchdunger, Elisabeth, Pascal, Furet, Druker, Brian J
Format:	Artikel
Sprache:	eng
Schlagworte:	Adenosine Triphosphate - metabolism Benzamides Binding Sites Cloning, Molecular Enzyme Inhibitors - pharmacology Humans Imatinib Mesylate Kinetics Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics Models, Molecular Piperazines - pharmacology Point Mutation Protein Conformation Protein-Tyrosine Kinases - antagonists & inhibitors Protein-Tyrosine Kinases - chemistry Pyrimidines - pharmacology Recombinant Fusion Proteins - antagonists & inhibitors Recombinant Fusion Proteins - chemistry Recombinant Proteins - antagonists & inhibitors Recombinant Proteins - chemistry Sensitivity and Specificity Substrate Specificity
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!